Latest news
25 items- PRResolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business OfficerHighly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.EDINBURGH, Scotland and LONDON, Sept. 10, 2025 /PRNewswire/ -- Resolution Therapeutics ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces the appointment of Lucy Singah as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CB
- SECSEC Form 15-12G filed by Alexion Pharmaceuticals, Inc.15-12G - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- SECSEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)
- INSIDERSEC Form 4: COUGHLIN CHRISTOPHER J returned 42,347 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: FRIEDMAN PAUL A returned 12,840 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: SARIN ARADHANA returned 120,253 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Reinsdorf Judith A returned 14,150 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Dunsire Deborah returned 14,629 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Chiniara Ellen returned 116,850 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Goff Brian returned 150,832 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Brennan David R returned 20,873 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Mollen John T returned 15,336 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Carino Tanisha returned 59,226 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Nader Francois returned 13,921 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: Franchini Indrani Lall returned 116,075 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4 filed by Alexion Pharmaceuticals, Inc.4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
- INSIDERSEC Form 4: ORLOFF JOHN J returned 146,511 units of Common Stock to the company, closing all direct ownership in the company4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)
ALXN FAQ
5 questionsWhere does ALXN stock trade?
Alexion Pharmaceuticals, Inc. (ALXN) is listed on NASDAQ.What sector and industry is ALXN in?
Alexion Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Alexion Pharmaceuticals, Inc. go public?
Alexion Pharmaceuticals, Inc. (ALXN) completed its IPO in 1996.What companies are similar to ALXN?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare ALXN side-by-side with any of them on Quantisnow.How can I track ALXN on Quantisnow?
Quantisnow aggregates Alexion Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALXN to receive live email and push alerts on every new disclosure.